Category Archives: Biochemistry

Dublin, Dec. 11, 2020 (GLOBE NEWSWIRE) -- The "India Biopesticides Market Outlook to 2024 - Government Impetus to Improve Soil Health Further Supported by Flexible Registration Process Expected to Pose Healthy Growth" report has been added to ResearchAndMarkets.com's offering.

The report titled India Biopesticides Market Outlook to 2024 - Government Impetus to Improve Soil Health Further Supported by Flexible Registration Process Expected to Pose Healthy Growth provides a comprehensive analysis of Biopesticides market in India.

The report focuses on market size, market segmentation by unorganized and organized sector, By Origin (Microbial, Biochemical Biopesticides and PIPS), by India Biofungicides Market Segmentation (Trichoderma Viride and Harzianum, Pseudomonas Fluorescens, Bacillus Subtilis/ Pumilus, Ampelomyces Quisqualis, Fusarium Proliferatum), by India Bioinsecticides Market Segmentation (Bacillus Thuringiensis Variant Kurstaki, Beauveria Bassiana, Verticillium Lecanii, Metarhizium anisopliae, Paecilomyces lilacinus and Others), by By Target Pests (Sucking Insects, Soil Insects, Caterpillars, Nematodes), by Crops, by Imported and Indigenous Biopesticides, Biopesticides Consumption by Regions and States.

The report also covers the competitive landscape, government role and regulations, growth restraints, drivers. The report concludes with market projections highlighting opportunities and cautions.

Key Topics Covered:

1. Executive Summary

2. Research Methodology2.1. Market Definitions2.2. Abbreviations2.3. Market Size and Modelling

3. India Biopesticides Market Overview and Genesis, 2013-20183.1. Agricultural Overview

4. Comparative Analysis of India Biopesticides Market with Global Market4.1. Recent Investment Details (Mergers, Acquisition and Partnerships in Biopesticides Market)

5. Value Chain Analysis of India Biopesticides Market

6. India Biopesticides Market Size, FY'2013-FY'2019(P)

7. India Biopesticide Market Segmentation, FY'2013-FY'2019(P)7.1. By Origin (Microbial, Biochemical Biopesticides and PIPS), FY'2015 & FY'2019(P)

7.2. India Biofungicides Market Segmentation (Trichoderma Viride and Harzianum, Pseudomonas Fluorescens, Bacillus Subtilis/ Pumilus, Ampelomyces Quisqualis, Fusarium Proliferatum), FY'2015 and FY'2019(P)7.3. India Bioinsecticides Market Segmentation (Bacillus Thuringiensis Variant Kurstaki, Beauveria Bassiana, Verticillium Lecanii, Metarhizium anisopliae, Paecilomyces lilacinus and Others), FY'2015 and FY'2019(P)7.3.1. By Target Pests (Sucking Insects, Soil Insects, Caterpillars, Nematodes), FY'2015 and FY'2019(P)7.4. By Organized and Unorganized Market, FY'2015 and FY'2019(P)7.5. By Crops, FY'2015 and FY'2019(P)7.6. By Imported and Indigenous Biopesticides, FY'2013-FY'2019(P)7.7. India Biopesticides Consumption by Regions and States, FY'2017 and FY'2019(P)

8. Growth Drivers and Restraints for India Biopesticides Market8.1. Growth Drivers

8.2. Growth Restraints

9. Average Price of Key Biopesticides

10. Snapshot on India Bioherbicides Market

11. Snapshot on Liquid Formulation of Biopesticides

12. Decision Making Process Used by Farmers Before Purchasing Biopesticide

13. Government Policies and Regulations in Biopesticides Market in India

14. Competitive Scenario of Major Players in India Biopesticides Market, Fy' 201814.1. Competitive Analysis of Players in India Biopesticide Market14.2. Market Share of Major Players in India Organized Biopesticides Market, FY'201814.3. Biopesticides Registrant in India

15. Company Profiles of Major Companies in India Biopesticides Market, 201815.1. EID Parry15.2. T Stanes15.3. Fortune Biotech15.4. Excel Crop Care15.5. International Panaacea Limited15.6. Biotech International Limited15.7. Kan Biosys15.8. Pest Control India (PCI)15.9. PJ Margo15.10. Prathibha Biotech15.11. Company Profiles of Other Major Players (Zytex Biotech and Camson Bio Technologies), FY'2018

16. India Biopesticides Market Future Outlook and Projections, FY'2019-FY'2024E16.1. India Biopesticides Market Future Segmentation, FY'2024

16.2. Cause and Effect Relationship between Industry Factors and India Biopesticides Industry Prospects

17. Analyst Recommendations for India Biopesticides Market

For more information about this report visit https://www.researchandmarkets.com/r/os6ldt

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read this article:
Biopesticides Industry in India to 2024 - Government Impetus to Improve Soil Health Further Supported by Flexible Registration Process - GlobeNewswire

This article was originally published here

J Contemp Brachytherapy. 2020 Oct;12(5):420-426. doi: 10.5114/jcb.2020.100374. Epub 2020 Oct 30.

ABSTRACT

PURPOSE: The aim of this study was to compare short-term oncologic outcomes and toxicity of focal or partial low-dose-rate brachytherapy (focal/partial LDR-BT) with whole gland low-dose-rate brachytherapy (whole LDR-BT) in localized prostate cancer patients.

MATERIAL AND METHODS: Medical records of eligible patients who underwent focal/partial LDR-BT and whole LDR-BT between 2015 and 2017 at our institution were reviewed retrospectively. Clinical characteristics and pathologic outcomes were compared between focal/partial LDR-BT group and whole LDR-BT group. Biochemical recurrence-free survival was analyzed using Kaplan-Meier method and difference between two groups was assessed with log-rank test. Genitourinary and rectal toxicity were also evaluated between the two groups.

RESULTS: Of the 60 patients analyzed, 30 focal/partial LDR-BT patients and 30 whole LDR-BT brachytherapy patients were included. Relative to the whole LDR-BT group, the focal/partial LDR-BT group had significantly higher initial PSA level (p = 0.002), smaller number of implanted seeds (p < 0.001), and shorter follow-up duration (p < 0.001). There was no significant difference between the two groups with regard to prostate volume, biopsy Gleason score, and risk group stratification. The 3-year biochemical recurrence-free survival estimates for focal/partial LDR-BT group and whole LDR-BT group were 91.8% and 89.6%, respectively, which was not significantly different (p = 0.554). Genitourinary symptoms were significantly worse in whole LDR-BT group than in focal/partial LDR-BT group. The incidence of rectal toxicity was similar between two groups.

CONCLUSIONS: Our findings indicate that the focal/partial LDR-BT is comparable to the whole LDR-BT with respect to short-term biochemical recurrence and toxicities.

PMID:33299430 | PMC:PMC7701917 | DOI:10.5114/jcb.2020.100374

Original post:
Feasibility and early toxicity of focal or partial brachytherapy in prostate cancer patients - DocWire News

David Cortez, Richard N. ArmstrongChairforInnovation inBiochemistryandprofessor of biochemistry, has been named interimchairintheDepartment ofBiochemistrybeginningJan. 1.

This follows the departure of John York, who was recently named chief science officer of food technology startup Impossible Foods and will be moving to California.

The investments that Dr. York directed into the infrastructure, training and people in the Department of Biochemistry have been transformative. Simply put, I want to build on this momentum, Cortez said. I look forward to working with the faculty, staff and trainees to continue our shared pursuit of excellence in science discovery and education. The people in this department and at Vanderbilt make it special, and I will do everything I can to support them as they pursue their goals.

Cortez, also associate director for basic sciences research at theVanderbilt-Ingram Cancer Center, specializes in understanding the function of DNA damage response pathways in maintaining a healthy genome, and in understanding how those pathways are activated. His labs current projects include identifying new proteins involved in DNA damage response and developing cancer therapeutics that target that response. The trans-institutional Cortez lab is connected to theGenome Maintenance Research Programwithin the VICC,the Center in Molecular Toxicology,Vanderbilt Institute of Chemical Biologyand the Department of Biochemistry.

During Yorks tenure, the Department of Biochemistry became 2019s top NIH-funded department in the nation.

During Yorks tenure, the Department of Biochemistry became 2019s top NIH-funded department in the nation. With an expanded and diversified faculty, he invigorated the graduate and development research programs, building a shared sense of purpose and community in the department. These efforts fostered an environment that supports discovery science and curiosity-driven research, saidLawrence Marnett, dean of School of Medicine Basic Sciences.

My time at Vanderbilt has been a remarkable professional experience and a tremendous privilege. Together, we have built a discovery-science environment for recruitment of diverse faculty and trainees, York said. The commitment to academic excellence and pursuit of transformative solutions to problems facing the world shared by my colleagues and students is unparalleled, and the department is well-positioned to continue its steep upward trajectory. Iintend to maintain the One Vanderbilt spirit of collaboration in the next phase of my career and will remain a friend to all the wonderful colleagues I have worked with over the past nine years.

It has been an honor to work with John, who not only significantly increased funding for the Department of Biochemistry, but has also helped to establish Vanderbilt as a top destination for world-class faculty and scholars determined to make life-changing discoveries, said Provost and Vice Chancellor for Academic AffairsSusan R. Wente. I wish him luck with his next venture and am confident that David Cortez has the dedication and the visionary leadership to continue the remarkable momentum that John has established.

Cortez graduated summa cum laude from the University of Illinois at Champaign-Urbana with highest honors in biology and biochemistry and received his Ph.D. in molecular cancer biology from Duke University. After postdoctoral training as a Jane Coffin Childs Fellow with Stephen Elledge at the Baylor College of Medicine, he joined Vanderbilt in 2002. In 2009, Cortez was named professor of biochemistry and Ingram Professor of Cancer Research. His achievements have been recognized with the Howard Temin Award from the National Cancer Institute, the Wilson S. Stone Memorial Award from the MD Anderson Cancer Center and a Pew Scholar Award from the Pew Charitable Trusts. Cortez is a member of the editorial boards of the journalsCell ReportsandScience Advances, and in 2017 he was named a fellow of the American Association for the Advancement of Science.

While the departure of an esteemed colleague is never good news, we are proud of what John has built and wish him well in this exciting new endeavor. Our biochemistry students and faculty have benefitted tremendously from the hard work and dedication that John brought to his role, Marnett said. We are also extremely fortunate to have a world-class scientist like Dave Cortez assume the leadership of the department and continue its momentum. I look forward to working with him and anticipate he will be very successful.

Here is the original post:
Cortez named interim chair in the Department of Biochemistry; York named Impossible Foods chief science officer - Vanderbilt University News

Impossible Foods continues to accelerate its innovation strategy with its new hire of Vanderbilt University Biochemistry Department Chair Dr. John D. York, Ph.D., as chief science officer. The company plans to double the number of scientistson its team within a year as part of its plan to heavily invest in R&D.

The privately held food tech startup was founded in 2011 by Dr. Patrick O. Brown, M.D., Ph.D., professor emeritus of biochemistry at Stanford University, and a former Howard Hughes Medical Institute investigator, as a way to develop nutritious meat and dairy products from plants with a much smaller environmental footprint than meat from animals.

Impossible Foods scientists best-known achievement to date is the ImpossibleBurger. Impossible Foods first launched its plant-based Impossible Burger in retail stores in September 2019, and only a year later the product has expanded its reach to big retail names like Albertsons, The Kroger Co., Traders Joesand Walmart.

Under Yorks leadership, Impossible Foods will continue to build its food technology platform and expand basic research capabilities to accelerate next-generation plant-based products such as Impossible Pork, milk, steak and other foods.

Yorks first day at Redwood City, California-basedImpossible Foods will be Jan. 4. He will serve on Impossible Foods senior leadership team and oversee research and development, and product innovation. He will report directly to Brown, the company's CEO.

Throughout his career, John has contributed to discoveries in biochemistry thanks to his curiosity and risk tolerance, said Brown. Just as important, hes a proven and strong mentor and team leader. Im confident that John will make an immediate, positive contribution and quickly become an inspiring role model within our expanding R&D team.

York, a former Investigator for the Howard Hughes Medical Institute, has led the Department of Biochemistry at Vanderbilt University since 2012. His team paved the way for discoveries in protein structure and function, cell signaling and molecular genetics. The Midwest native received his undergraduate degree from the University of Iowa and his Ph.D. in molecular cell biology and biochemistry from Washington University, in Saint Louis.

The opportunity to use biochemistry to save the planet is a spectacular motivation, York said. That Impossible Foods is rooted in discovery science and engineering as a key innovation platform resonates with my core values and lifelong pursuits in research. Its an honor and privilege to be part of the team, and I look forward to the limitless future possibilities.

Impossible Foods intellectual property encompasses how to replicate the sensory experience of animal-derived meat, including how it tastes, cooks, sizzles and smells.

The company has raised approximately $1.5 billion since its founding in 2011, including $700 million in two rounds this year.The plant-based company said that it raised $200 million in its funding round in August led by New York-based new investor Coatue.

Other investors include Mirae Asset Global Investments, Khosla Ventures, Bill Gates, Google Ventures, Horizons Ventures, UBS, Viking Global Investors, Temasek, Sailing Capital and Open Philanthropy Project.

Further, Impossible Foods has been keeping busy during the pandemic, filling the needs of a growing plant-based category after retailers experienced meat shortages during the height ofpandemic stockpiling. It even entered the direct-to-consumer space with an e-commerce site,indicatingthat DTC is a natural fit for this pandemic worldas consumer behavior shifts.

Read more here:
Impossible Foods Accelerates Innovation Strategy With New Hire - Progressive Grocer

LSU CANCER RESEARCH: TheAmerican Association for the Advancement of Science has honoredSuresh Alahari, of theLSU Health New Orleans School of Medicine, as a fellow, in recognition of hiscontributions in cancer research and teaching, with a focus on signal transduction. His research interests include the biochemistry of cell adhesion and the mechanism of action of Nischarin in tumor cell migration and invasion. Nischarin is a novel protein Alahari discovered that is involved in a number of biological processes, including the regulation of breast cancer cell migration and movement. He joined the LSU Health New Orleans faculty in 2004.

LSU HEALTH GRADUATE STUDIES: TheAssociation for Research in Vision and Ophthalmology has awarded its Emerging Advocate Award to Jarrod C. Harman, a student at LSU Health New Orleans School of Graduate Studies. The award recognizes ARVO members who have made efforts to integrate advocacy as part of their professional efforts early in their careers. Harman, who is pursuing a doctorate of philosophy degree in biochemistry and molecular biology, has been active in the Student Government Association at LSU Health New Orleans. He served as vice president and interim president. His advocacy work has included lobbying in Washington, D.C., for funding for the National Eye Institute and working with the Louisiana Lions Eye Foundation to perform vision screenings at inner-city primary schools.

OCHSNER BAPTIST: TheWomens Wellness and Survivorship Center at Ochsner Baptist will be the beneficiary of the New Me Time Challenge presented by the Crescent City Classic and Ochsner Health. The virtual challenge,focused on physical and mental health, is running through Jan. 14. The entry cost for either the 30-mile individual challenge or the 100-mile team challenge is $35. For every 5 miles logged, participants will unlock health-focused tips along with special access to wellness and nutrition offers provided by Ochsner Health. To register,visit http://www.ccc10k.com. For information, email customer.service@ccc10k.com.

SURVIVORS OF SUICIDE SUPPORT GROUP:NOLA Survivors of Suicide Loss is a free, peer-led support group for adults who have lost a loved one to suicide. The usual Zoom meeting time for the group is from 6:30 p.m. to 8 p.m. on the second and fourth Wednesdays of each month; to register to attend a meeting, visitnolasurvivors.com/contact-usor email survivors.nola@gmail.com.

UNIVERSITY OF HOLY CROSS:Free telecounseling is available from 11 a.m. to 8 p.m. Monday through Thursday from the University of Holy Cross. To schedule a session, call (504) 398-2168.

Read the rest here:
LSU cancer researcher recognized, and other metro area health news - NOLA.com

Medical schools willing to invest in qualified students from disadvantaged backgrounds can impact the nations physician workforce by increasing the number of doctors serving in regions designated as health professional shortage areas and medically underserved populations, according to a Wayne State University School of Medicine study published in Academic Medicine, the Journal of the Association of American Medical Colleges.

Impact of a 50-Year Premedical Postbaccalaureate Program in Graduating Physicians for Practice in Primary Care and Underserved Areas,a review of the impact of the School of Medicines Post Baccalaureate Program over its 50-year life, found that the program has been successful in graduating a large proportion of physicians from disadvantaged and diverse backgrounds. Many of these physicians went on to practice in regions with a shortage of doctors and in areas with underserved populations, accomplishing the goals of addressing the broad primary health care needs of all Americans, said lead author Herbert Smitherman Jr., M.D., M.P.H., professor of Internal Medicine and vice dean of Diversity and Community Affairs.

The study set out to evaluate the effectiveness of the School of Medicines premedical Post Baccalaureate Program in achieving its goals, measured by medical school, medical school graduation, primary care specialization and current practice.

The programs foundational goals are to provide academically-qualified students from lower socioeconomic, disadvantaged and underrepresented backgrounds the opportunity to become physicians; to identify and select students likely to return to their underserved communities to practice; to increase access to health care in underserved communities and therefore improve health outcomes; to increase the number of primary care physicians both locally and nationally; and to increase diversity in the physician workforce in an effort to address health inequities, disparities and social determinants of health.

To ensure that qualified minorities continued to have the opportunity to enter medical school, in 1969 the WSU School of Medicine established the Post Baccalaureate Program, the first of its kind in the nation. Initially launched to address the dearth of African American students entering medical schools, the free program immerses students into a year-long education in biochemistry, embryology, gross anatomy, histology and physiology. Many who graduated from the program were accepted into the WSU School of Medicine, but the program also served as a major pipeline for Black students into medical schools across the nation.

Five African American students were admitted into the initial program, which was so successful that in 1972 it expanded to accept 10 students. The first Post Baccalaureate Program student graduated from the Wayne State University School of Medicine in 1974. The program expanded its efforts to increase underrepresented minorities in medicine. Following the U.S. Supreme Courts 1978 Bakke decision, the program cast a wider net yet again, accepting socio-economically disadvantaged students regardless of race or ethnicity.

In the 1970s and early 1980s the program served as a major pipeline for the admission of African American students to medical schools across the country. During the 1980s and 1990s, the WSU School of Medicine earned the distinction of graduating more African American physicians than any other medical school in the nation, with the exception of Howard University in Washington, D.C., and Meharry Medical College in Nashville. Representatives of U.S. medical schools flocked to Detroit to learn how WSU accomplished the achievement.

Today, as many as 200 Michigan undergraduates apply for the program each year. A maximum of 16 students are accepted annually.

The study found that of 539 students who graduated from the program between 1979 and 2017:

463 (85.9%) successfully completed, then matriculated to the School of Medicine. Of those, 401 (86.6%) obtained a medical degree.Of the 401 who obtained a medical degree, 233 were female.The average investment per Post Baccalaureate Program student was approximately $52,000; for a M.D. graduate approximately $77,000. The majority of doctors who graduated the program (72.1%) lived in areas identified as medically underserved or having a shortage of physicians when they were admitted to the program. Today, 82% practice in such areas. Most practice primary care medicine.The programs total cost for 50 years was $32 million, an average investment of approximately $52,000 per student, and approximately $77,000 per graduated physician.

Today there are 250 similar programs in the United States, but a study by the AAMC found only 63 focused on underrepresented in medicine students and only 18 of those had explicit diversity-based missions. Because the WSU program cost structure is flexible, the study team reported, universities with existing medical education resources can readily adapt the program to meet their needs.

Other members of the study team include Anil Aranha, Ph.D., associate director of Diversity and Inclusion; DeAndrea Matthews, D.R.E., director of the Office of Diversity and Inclusion; Andrew Dignan, chief information officer and chief administrative officer for Health Centers Detroit Foundation Inc.; Mitchell Morrison, M.P.H., former intern in the Office of Diversity and Inclusion and now a clinical research associate for IQVIA/Roche & Genentech; Eric Ayers, M.D., associate professor of Medicine and Pediatrics; Leah Robinson, Ph.D., director of Academic Support for the Office of Diversity and Inclusion; Lynn Smitherman, M.D., associate professor of Pediatrics; Kevin Sprague, M.D., associate dean of Admissions; and Richard Baker, M.D., vice dean of Medical Education.

Excerpt from:
Study finds Post Baccalaureate Program successful in diversifying physician workforce and helping underserved regions and populations - The South End